DV
Dividend Vision

AKTS — Aktis Oncology, Inc. Common stock

Aktis Oncology, Inc. Common stock (AKTS)

Total return is 11.3% over the past 0.6 years, 1.1 points behind SPY at 12.4%.

Aktis Oncology is a clinical-stage oncology company developing targeted radiopharmaceuticals designed to treat solid tumors, with lead product candidates in Phase 1b trials for cancers including urothelial, breast, lung, colorectal, and cervical cancers. The company does not currently distribute dividends. Aktis Oncology appeals to investors seeking exposure to early-stage cancer therapeutics development rather than current income.

AKTS key facts

Asset type
Stock
Asset class
Equity
Inception date
01/09/2026
Last close
$24.93
Market cap
$1,375,855,616
Average volume
229800.0
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.21